SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on September 28, 2007. The registrant is a Colorado-based company focused on medical diagnostics. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Operational Updates
- Item 7.01 (Regulation FD Disclosure): The company announced further positive results regarding its appendicitis triage blood test.
- Study Details: The results stem from a large, multiple-hospital study.
- Exhibit 99.1: The full press release detailing these results is attached as an exhibit to this filing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the context of the clinical study results. No unusual items or contingencies are disclosed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific statistical data and clinical outcomes of the appendicitis triage blood test.
- Verify the scope and methodology of the "large multiple hospital study" referenced in the announcement.
- Check subsequent filings for any financial impact or commercialization plans resulting from these positive results.
- Note that the metadata provided in the request incorrectly identified the company as "Riot Platforms, Inc."; the filing explicitly names AspenBio Pharma, Inc.